Precautions before starting tofacitinib in persons with rheumatoid arthritis

Tofacitinib is an immunosuppressive and disease-modifying therapy in rheumatoid arthritis. It may result in many infections flaring up. It is important to take precautions of all kinds (cardiovascular, malignancy, infections etc.) before starting tofacitinib. In this article, we have highlighted imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Swarnakar, Raktim, Yadav, Shiv Lal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850994/
https://www.ncbi.nlm.nih.gov/pubmed/36683637
http://dx.doi.org/10.12998/wjcc.v10.i36.13467
_version_ 1784872310494199808
author Swarnakar, Raktim
Yadav, Shiv Lal
author_facet Swarnakar, Raktim
Yadav, Shiv Lal
author_sort Swarnakar, Raktim
collection PubMed
description Tofacitinib is an immunosuppressive and disease-modifying therapy in rheumatoid arthritis. It may result in many infections flaring up. It is important to take precautions of all kinds (cardiovascular, malignancy, infections etc.) before starting tofacitinib. In this article, we have highlighted important steps where we need to take precautions before starting tofacitinib.
format Online
Article
Text
id pubmed-9850994
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-98509942023-01-20 Precautions before starting tofacitinib in persons with rheumatoid arthritis Swarnakar, Raktim Yadav, Shiv Lal World J Clin Cases Letter to the Editor Tofacitinib is an immunosuppressive and disease-modifying therapy in rheumatoid arthritis. It may result in many infections flaring up. It is important to take precautions of all kinds (cardiovascular, malignancy, infections etc.) before starting tofacitinib. In this article, we have highlighted important steps where we need to take precautions before starting tofacitinib. Baishideng Publishing Group Inc 2022-12-26 2022-12-26 /pmc/articles/PMC9850994/ /pubmed/36683637 http://dx.doi.org/10.12998/wjcc.v10.i36.13467 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Letter to the Editor
Swarnakar, Raktim
Yadav, Shiv Lal
Precautions before starting tofacitinib in persons with rheumatoid arthritis
title Precautions before starting tofacitinib in persons with rheumatoid arthritis
title_full Precautions before starting tofacitinib in persons with rheumatoid arthritis
title_fullStr Precautions before starting tofacitinib in persons with rheumatoid arthritis
title_full_unstemmed Precautions before starting tofacitinib in persons with rheumatoid arthritis
title_short Precautions before starting tofacitinib in persons with rheumatoid arthritis
title_sort precautions before starting tofacitinib in persons with rheumatoid arthritis
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850994/
https://www.ncbi.nlm.nih.gov/pubmed/36683637
http://dx.doi.org/10.12998/wjcc.v10.i36.13467
work_keys_str_mv AT swarnakarraktim precautionsbeforestartingtofacitinibinpersonswithrheumatoidarthritis
AT yadavshivlal precautionsbeforestartingtofacitinibinpersonswithrheumatoidarthritis

Ejemplares similares